Liquidia Corp.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:LQDA
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 713 out of 921
Universe
Global Universe 13312 out of 16216
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Kaken Pharmaceutical Co., Ltd. |
28.9
Medium
|
467 out of 921 |
FDC Ltd. |
32.5
High
|
642 out of 921 |
Liquidia Corp. |
33.8
High
|
713 out of 921 |
Sun Pharma Advanced Research Co. Ltd. |
41.2
Severe
|
901 out of 921 |
Saudi Pharmaceutical Industries & Medical Appliances Corp. |
41.7
Severe
|
909 out of 921 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Liquidia Corp.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Liquidia Corp.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted Liquidia Corp.'s ESG Risk Rating in the last three years
Highest Controversy Level
![blurred controversy level](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-level-blur.jpg)
Contributing Events
![blurred controversy events](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-events-blur.jpg)
Highest Controversy Events Locations
![world map blurred](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-events-map-blur.jpg)